Proveca is the future Engine of Children’s Medicine
Proveca is a pharmaceutical company which has established the unique set of competencies required to develop medicines for children and establish a brand which is trusted by prescribers and parents.
The world has many different items made specifically for children – baby milk, toys, education, clothes, the list goes on, but today many medicines given to children are adult formulations not designed or licensed for children.
Proveca is leading the way in changing this paradigm by providing the right medications for children. Proveca understands that health care providers and parents need confidence regarding the safety, efficacy, right dosage form and palatability of a medicine for a child. Therefore Proveca ensures all of its medicines are designed with the child in mind.
What sets us apart
Only children’s medicines
Proveca is focused solely on the development and licensing of Children’s medicines. The team draws on many years of paediatric experience in formulation, regulatory, medical and commercial.
Proveca’s expertise in this area is valued by health care providers as we work with them to understand the problems associated with providing the right management and medications specifically for children.
Making a difference
Proveca are developing more than just the formulations, we conduct clinical trials to demonstrate the efficacy and safety of our medicines as well as demonstrating the effects on quality of life, and we aim to register them as widely as possible to benefit children all over the world.
Proveca also look to make a difference by helping to educate health care providers and carers about the conditions of importance to them and how the child can be managed effectively. To this end, Proveca has been providing an educational series to healthcare professionals and is co-ordinating the development of relevant European guidelines which will help to educate and inform those who treat and manage chronically sick children.
Identifying the child’s unmet need
Working with clinicians, pharmacists, nurses, parents, and patients Proveca is able to understand the problems around medications such as lack of dose suitability or administration difficulty. As a result, Proveca’s research and development department are continuously looking at suitable formulation alternatives. This can involve looking to provide age appropriate dose forms, assist with adherence and improve palatability in order to improve symptom control and quality of life for the child and their carers.
Reaching children around the world
Proveca have a global ambition in the paediatric medicine market, which is valued at £100 billion per annum in the US, Canada, Europe and Japan.
Proveca will be the leading Children’s Pharmaceutical company in the world by 2030, aiming to licence and distribute to many countries and continents to ensure children have global access to the right medications.
Published June 9 2022
Proveca enters an exclusive agreement with Mawdsley Brooks Brazil, part of global pharmaceutical services provider Mawdsleys, to commercialise and distribute Sialanar® in Brazil.
Published April 6 2022
Proveca Ltd is excited to announce a significant agreement outside Europe with Biopas Laboratories based in Colombia. Biopas will commercialise and distribute Sialanar® exclusively throughout Spanish speaking territories in South America.
Published March 9 2022
Proveca Pharma Ltd are excited to announce their new partnership with ExCEEd Orphan to commercialise and distribute Sialanar exclusively in Central and Eastern Europe (CEE). Under the terms of the agreement, ExCEEd Orphan will have exclusive rights to seek reimbursement, distribute and market Sialanar within its paediatric indication in several CEE countries where they operate as experts in rare diseases.
Reviewed November 2021